Single-chain antibody for targeting Reg3A

A single-chain antibody, heavy chain technology, applied in the biological field, can solve problems such as reduced patient survival rate

Inactive Publication Date: 2017-11-21
CHINA PHARM UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows for researchers studying how an immune system works by identifying specific proteins called regulator 3 A (R-3Al) which are involved with controlling certain aspects of blood clotting during inflammation processes such as cancer growth. These regulators help control bleeding more effectively than traditional treatments like chemotherapy.

Problems solved by technology

Technological Problem: The Patented Disc describes how certain regulatory domains found within this group play an important role in controlling growth processes such as inflammations and carcinogenic transformation in colon cancer researchers' laboratories. These regions include two types - one containing signals involved in transmitting receptor functions and another containing sequences associated with other components like DNA binding sites. By comparing these findings across multiple studies, we identified three distinct groups of regulators known as Regulato Group Libraries (regions I–III).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Single-chain antibody for targeting Reg3A
  • Single-chain antibody for targeting Reg3A
  • Single-chain antibody for targeting Reg3A

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Phage Antibody Library Screening Anti-Reg3A Single Chain Antibody

[0030] 1. Antigen Reg3A

[0031] The Reg3A protein (Q06141-1) used in the present invention is purchased from Beijing Yiqiao Shenzhou Biotechnology Co., Ltd., which contains 175 amino acids and has a purity of >97%.

[0032] 2. Preparation of Escherichia coli host strain TG1 with sex cilia

[0033] TG1 was streaked from the plate in the glycerol cryopreservation tube, inoculated on the M9 medium plate, and cultured upside down at 37°C for 36 hours. Pick a single clonal colony, inoculate it in 5ml 2×YT medium, and cultivate overnight at 37°C on a shaker. The next day, 1 / 100 dilution was inoculated in fresh 2×YT medium, and cultured on a shaker at 37°C to logarithmic phase (OD 600 0.4-0.6), and then infected with phage.

[0034] 3. Preparation of Helper Phage

[0035] Add the helper phage to 200 μL TG1 bacterial culture solution (OD 600 0.5), after 30 minutes in a water bath at 37°C, add it

Embodiment 2

[0055] Example 2 Sequencing and analysis of Reg3A scFv

[0056] Sequencing results showed that five Reg3A scFv gene sequences were successfully obtained, using IMGT / V-QUEST ( http: / / www.imgt.org / ) analyzed the Reg3A scFv gene sequence, and the analysis results showed that: the heavy and light chain variable regions of the Reg3A scFv named A5 and their CDR1-3 region gene sequences are shown in SEQ ID NO.1-8; the Reg3A scFv heavy named C2 1, the gene sequence of the light chain variable region and its CDR1-3 regions are shown in SEQ ID NO.9-16.

Embodiment 3

[0057] Preparation and purification of embodiment 3 Reg3A scFv

[0058] PCR amplification of Reg3A scFv gene

[0059] The Reg3A scFv gene was amplified by PCR using the single clone screened from the phage library and correctly sequenced and analyzed as a template. EcoR I and Xho I were selected as upstream and downstream restriction sites respectively, and primers were designed using Primer5.0, wherein the sequences of A5-F, C2-F (upstream primers) and A5-R, C2-R (downstream primers) were:

[0060] A5-F CCGGAATTCCAGGTGGCAGCTGCAGGAGT

[0061] A5-R CCGCTCGAGACGTTTGATATCCACTTTGGTCCC

[0062] C2-F CCGGAATTCTCCAGGTACCTTGAAGGAGTCTGG

[0063] C2-R CCGCTCGAGACGTTTGATCTCCACCTTGGTCC

[0064] The reaction system was 50 μL, and the reaction conditions were 94°C for 4 min, 94°C for 30 s, 57°C for 45 s, 72°C for 1 min, 29 cycles, 72°C for 10 min, and storage at 4°C. Take 5 μL of the final product for identification on 1% agarose gel electrophoresis. Reg3A scFv gene of about 750bp was am

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a single-chain antibody capable of specifically recognizing Reg3A protein, including the nucleotide sequence and amino acid sequence of the heavy and light chain variable regions encoding the protein, and the CDR region determining the specificity of the antibody. In the present invention, a high-affinity single-chain antibody targeting Reg3A protein is screened out through a phage antibody library, and then the Reg3A single-chain antibody is obtained through construction, expression, and purification. The Reg3A single-chain antibody of the present invention can specifically bind to Reg3A, so it can treat or detect diseases related to excessive and abnormal expression of Reg3A.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products